Elisabeth Wassner-Fritsch

1.9k total citations
20 papers, 1.3k citations indexed

About

Elisabeth Wassner-Fritsch is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Elisabeth Wassner-Fritsch has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 14 papers in Genetics and 11 papers in Oncology. Recurrent topics in Elisabeth Wassner-Fritsch's work include Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Elisabeth Wassner-Fritsch is often cited by papers focused on Lymphoma Diagnosis and Treatment (18 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Monoclonal and Polyclonal Antibodies Research (10 papers). Elisabeth Wassner-Fritsch collaborates with scholars based in Switzerland, United Kingdom and France. Elisabeth Wassner-Fritsch's co-authors include Philippe Solal‐Céligny, Gilles Salles, Guiyuan Lei, Franck Morschhauser, Michael Wenger, Guillaume Cartron, Robert Marcus, Anna Dmoszyńska, David Cunningham and G Stein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Elisabeth Wassner-Fritsch

20 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elisabeth Wassner-Fritsch Switzerland	12	1.1k	768	743	300	251	20	1.3k
Roswitha Forstpointner Germany	15	1.5k 1.3×	732 1.0×	1.1k 1.5×	182 0.6×	166 0.7×	38	1.7k
W. Hiddemann Germany	2	871 0.8×	432 0.6×	627 0.8×	134 0.4×	156 0.6×	2	969
David Belada Czechia	18	819 0.7×	327 0.4×	604 0.8×	176 0.6×	162 0.6×	167	1.1k
Charles Foussard France	12	885 0.8×	356 0.5×	601 0.8×	262 0.9×	85 0.3×	22	1.0k
Andrew Haynes United Kingdom	15	1.0k 0.9×	655 0.9×	516 0.7×	370 1.2×	106 0.4×	36	1.3k
J. Matthews United Kingdom	13	988 0.9×	428 0.6×	664 0.9×	196 0.7×	73 0.3×	20	1.1k
Andrej Vranovský Slovakia	8	675 0.6×	406 0.5×	450 0.6×	100 0.3×	113 0.5×	16	781
Daniel C. Scullin United States	13	650 0.6×	362 0.5×	586 0.8×	184 0.6×	233 0.9×	23	1.1k
C. G. A. Price United Kingdom	13	849 0.7×	426 0.6×	589 0.8×	202 0.7×	66 0.3×	15	1.1k
Dorothea Kofahl-Krause Germany	10	1.5k 1.3×	921 1.2×	984 1.3×	164 0.5×	41 0.2×	15	1.6k

Countries citing papers authored by Elisabeth Wassner-Fritsch

Since Specialization

Citations

This map shows the geographic impact of Elisabeth Wassner-Fritsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Wassner-Fritsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Wassner-Fritsch more than expected).

Fields of papers citing papers by Elisabeth Wassner-Fritsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth Wassner-Fritsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Wassner-Fritsch. The network helps show where Elisabeth Wassner-Fritsch may publish in the future.

Co-authorship network of co-authors of Elisabeth Wassner-Fritsch

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Wassner-Fritsch. A scholar is included among the top collaborators of Elisabeth Wassner-Fritsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Wassner-Fritsch. Elisabeth Wassner-Fritsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Delforge, Michel, Joshua Richter, Yaël C. Cohen, et al.. (2024). Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study. Blood. 144(Supplement 1). 4732–4732. 1 indexed citations

Wong, Sandy W., Habib Hamidi, Luciano J. Costa, et al.. (2023). Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. Frontiers in Immunology. 14. 1085893–1085893. 3 indexed citations

Pott, Christiane, Laurie H. Sehn, David Belada, et al.. (2019). MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. Leukemia. 34(2). 522–532. 20 indexed citations

Cheson, Bruce D., Peter C. Trask, John G. Gribben, et al.. (2016). Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. Annals of Hematology. 96(2). 253–259. 18 indexed citations

Dyer, Martin J.S., Marcos González, Martin Dreyling, et al.. (2016). Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. Haematologica. 102(4). 765–772. 21 indexed citations

Sehn, Laurie H., Neil Chua, Jiřı́ Mayer, et al.. (2016). Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. The Lancet Oncology. 17(8). 1081–1093. 227 indexed citations

Cheson, Bruce D., Marek Trněný, Kamal Bouabdallah, et al.. (2016). Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. Blood. 128(22). 615–615. 20 indexed citations

Dyer, Martin J.S., Andrew Grigg, Marcos González, et al.. (2014). Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study. Blood. 124(21). 1743–1743. 9 indexed citations

Morschhauser, Franck, Laurie H. Sehn, Mark Dixon, et al.. (2014). Pattern of Cytokine Release in Patients with Chronic Lymphocytic Leukemia Treated with Obinutuzumab and Possible Relationship with Development of Infusion Related Reactions (IRR). Blood. 124(21). 4674–4674. 10 indexed citations

10.

Cartron, Guillaume, Sophie de Guibert, Marie‐Sarah Dilhuydy, et al.. (2014). Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 124(14). 2196–2202. 125 indexed citations

11.

Morschhauser, Franck, Guillaume Cartron, Catherine Thiéblemont, et al.. (2013). Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study. Journal of Clinical Oncology. 31(23). 2912–2919. 157 indexed citations

12.

Davies, Andrew, John Radford, Guillaume Cartron, et al.. (2013). Obinutuzumab (GA101) Plus CHOP Or FC In Relapsed/Refractory Follicular Lymphoma: Final Data From The Maintenance Phase Of The Phase 1b GAUDI Study (BO21000). Blood. 122(21). 1814–1814. 2 indexed citations

13.

Radford, John, Andrew Davies, Guillaume Cartron, et al.. (2013). Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood. 122(7). 1137–1143. 101 indexed citations

14.

Salles, Gilles, Franck Morschhauser, Philippe Solal‐Céligny, et al.. (2013). Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study. Journal of Clinical Oncology. 31(23). 2920–2926. 129 indexed citations

15.

Dyer, Martin J.S., Andrew Grigg, Marcos González, et al.. (2012). Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000). Blood. 120(21). 3686–3686. 6 indexed citations

16.

Salles, Gilles, Franck Morschhauser, Catherine Thiéblemont, et al.. (2011). Efficacy and Safety of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma: Results From a Phase I/II Study (BO20999). Blood. 118(21). 268–268. 11 indexed citations

17.

Carlile, David, Georgina Meneses‐Lorente, Elisabeth Wassner-Fritsch, et al.. (2011). Pharmacokinetics of Obinutuzumab (GA101) in Patients with CD20+ Relapsed/Refractory Malignant Disease Receiving Concomitant Chemotherapy (Phase Ib Study BO21000),. Blood. 118(21). 3704–3704. 3 indexed citations

18.

Radford, John, Andrew Davies, Guillaume Cartron, et al.. (2011). Obinutuzumab (GA101) in Combination with FC or CHOP in Patients with Relapsed or Refractory Follicular Lymphoma: Final Results of the Phase I GAUDI Study (BO21000). Blood. 118(21). 270–270. 8 indexed citations

19.

Morschhauser, Franck, Guillaume Cartron, Catherine Thiéblemont, et al.. (2011). Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),. Blood. 118(21). 3655–3655. 12 indexed citations

20.

Marcus, Robert, Kevin Imrie, Philippe Solal‐Céligny, et al.. (2008). Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma. Journal of Clinical Oncology. 26(28). 4579–4586. 434 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact